Cortechs.ai | NeuroQuant<sup>®</sup> MS performance evaluation

NeuroQuant® MS performance evaluation

Quantitative measurements of lesion volume and lesion distribution have significant value for clinicians evaluating disease progression. Subjective measurements based on a clinician’s visual inspection and manual lesion segmentation are often vulnerable to inter-and intra-rater variability, resulting in low reproducibility. Thus, objective, automated lesion segmentation tools have been developed [1-3] to overcome these problems. Since the appearance of lesions may vary across different MRI protocols, incorporating multiple MRI studies provides more information to accurately delineate lesions.


More Resources

03/04/2026

Cortechs.ai and Siemens Healthineers Partner to Expand Global Access to NeuroQuant® Technologies

NeuroQuant® Lesion Surveillance will be integrated into the Siemens Healthineers Digital Marketplace to advance quantitative brain imaging worldwide.

02/25/2026

Cortechs.ai Announces MFDS (KFDA) Approval of Global-Leading NeuroQuant® V5 Platform in South Korea

MFDS approves NeuroQuant® V5 in South Korea, expanding AI-driven volumetric neuroimaging and clinical decision support.

02/24/2026

Financial Conflict Of Interest Policy Applicable To NIH Awards

02/20/2026

NeuroQuant® PET: FDA 510(k)-Pending Advancement in Molecular Dementia Imaging

FDA 510(k)-Pending NeuroQuant® PET delivers automated, standardized quantification for amyloid, tau, and FDG imaging in dementia care.

02/19/2026

How Cortechs.ai Protects ePHI: HIPAA‑Aligned Controls—and Beyond

Cortechs.ai’s HIPAA-aligned, defense-in-depth security safeguards ePHI across AI workflows—exceeding baseline compliance standards.

02/11/2026

NeuroQuant Normative Database: Advancing Age‑ and Sex‑Specific Brain Volumetry

Learn how the latest updates to the NeuroQuant normative database white paper strengthen age- and sex-specific brain volumetry and enhance clinical confidence.
Scroll to Top